

Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results From a National Survey of Adults With Psoriasis in the United States

Teri Greiling,¹ Melodie Young,² Robert C. Higham,³ April Armstrong⁴


¹Department of Dermatology, Oregon Health & Science University, Portland, OR, USA; ²Mindful Dermatology, Modern Research Associates, Dallas, TX, USA; ³Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA; ⁴Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

INTRODUCTION


- Psoriasis affects about 3% of adults,¹ with prevalence of intertriginous involvement estimated at 3.2%–36%²
- A survey was conducted by the Harris Poll in the U.S. to understand the perspectives and burden of patients with plaque psoriasis (PsO) who use topical treatments to manage their disease
- This poster presents results from the subset of patients with psoriasis involvement in intertriginous areas

METHODS

- The survey was conducted online October 21 through November 24, 2021, among 507 U.S. adults aged 18+ years diagnosed with psoriasis by a healthcare provider (Figure 1)



- Participants had to use a topical treatment and not use a prescription injectable treatment for their psoriasis
- Response percentages were adjusted using a propensity score variable to adjust for respondents' propensity to be online and a model using ranked weights and Random Iterative Method weighting
- Patients with psoriasis in intertriginous areas were those who reported exhibiting symptoms in intertriginous areas when presented with a list of areas of the body or when aided with pictures in this area (Figure 2)
 - 10% of patients overall reported having genital psoriasis, but genital involvement is not included in the intertriginous assessment




RESULTS

Patient-Reported Psoriasis Signs and Symptoms in the Intertriginous Area


- Of the 507 respondents, 320 (64%) patients with PsO reported having had symptoms in intertriginous areas during the course of their disease, with between buttocks and armpits being the most commonly affected
- 40% of patients with psoriasis intertriginous area involvement did not report their PsO involved intertriginous areas until after they saw pictures of PsO in these areas (Figure 3)

Figure 3. Patients Reporting Symptoms in Intertriginous Areas Before Versus After Being Shown Pictures




Patient-Reported Burden of Intertriginous Psoriasis

- PsO in intertriginous areas has a negative impact on patients' lives, particularly their emotional well-being and their sex lives
- In the subset of patients with intertriginous psoriasis (n=320)
 - Patients with PsO in intertriginous areas reported that it makes them feel embarrassed (80%), anxious (79%), or depressed (69%)
 - Reported rates of emotional impact were numerically higher in patients with groin involvement (Figure 4)




- Intertriginous area PsO (n=320) particularly impacts patients' intimate and sexual relationships
 - Patients reported intertriginous PsO having a very strong or strong negative impact on sexual distress/anxiety (45%), intimate relationships (39%), and sexual function (37%; Figure 5)
 - Patients with groin involvement reported numerically higher rates of impact

Figure 5. Patient-Reported Very Strong/Strong Negative Impact of Intertriginous Area Psoriasis on Sexual Health




- Nearly all participants (97%) say their intertriginous PsO has some effect on their overall quality of life, and most (66%) say this impact is slightly or moderately negative (Figure 6)
 - Patients reporting a "very strong negative impact" on their quality of life was numerically higher in patients with groin involvement (16%) versus no groin involvement (6%) and in females (15%) versus males (6%)

Figure 6. Level of Negative Impact of Psoriasis in Intertriginous Areas on Overall Quality of Life



- Symptoms that cause the largest negative effects on the quality of life of those with PsO in intertriginous areas are itching (61%), scaling (53%), redness (49%), and skin cracking (46%) (Figure 7)

Figure 7. Patients' Psoriasis Signs and Symptoms Negatively Impacting Quality of Life



Patients' Perspective on Healthcare Provider (HCP) Visits

- Typical patient visits with HCPs about PsO vary, with some patients disrobing and others remaining fully clothed
 - Although 70% of patients with intertriginous area involvement showed their psoriasis to HCPs, the most common area of intertriginous involvement was least likely to be shown to an HCP
 - Of patients reporting intertriginous involvement, between the buttocks was the most common area (47%)
 - Yet only 19% of patients showed this area of their body to their HCPs (Figure 8)

Figure 8. Most Common Intertriginous Areas Shown to HCPs





Figure 9. Treatment Patterns and Preferences of Patients With Intertriginous Involvement



CONCLUSIONS

- Almost 2 in 3 patients with PsO reported symptoms in intertriginous areas at some point in the course of their disease
- PsO in intertriginous areas has a negative impact on patients' lives, particularly their emotional well-being and their sexual health
- Typical protocols for HCP visits seem to range from some patients disrobing, whereas others remained fully clothed
- Intertriginous areas where patients are most likely to exhibit symptoms are also the areas that they are least likely to show an HCP
- Most patients with PsO in intertriginous areas who are using different topical treatments for different parts of their body feel that the ability to use a single treatment would be beneficial and increase adherence (Figure 9)

REFERENCES

- Armstrong AW, et al. *JAMA Dermatol* 2021;157:940–946.
- Dopytalska K, et al. *Reumatologia* 2018;56:392–398.

DISCLOSURES

AA is an investigator and consultant for Arcutis Biotherapeutics, Inc. and received grants/research funding and/or honoraria; RCH is an employee of Arcutis Biotherapeutics, Inc. Additional disclosures can be provided on request.

ACKNOWLEDGEMENTS

- This study was supported by Arcutis Biotherapeutics, Inc.
- Thank you to the investigators and their staff for their participation in the trial.
- We are grateful to the study participants and their families for their time and commitment.
- Writing support was provided by Lauren Ramsey, PharmD, Alligent Biopharm Consulting, LLC, and funded by Arcutis Biotherapeutics, Inc.